NCT01943760

Brief Summary

Tramadol is a centrally acting analgesic, is primarily Indicated for the treatment of acute pain, moderate to severe. The hernioplasty in children is an outpatient procedure, and the possibility of postoperative analgesia with fewer systemic adverse effects such as nausea and vomiting make the tramadol infiltration a technique of interest. There is controversy about its effectiveness. The local effect of tramadol in hernioplasty was also studied by researchers with some better postoperative analgesia than with local anestetic . There are few studies with administration of tramadol for hernioplasty, Which led to the interest in this study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2012

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 9, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 17, 2013

Completed
Last Updated

September 17, 2013

Status Verified

September 1, 2013

Enrollment Period

1 year

First QC Date

September 9, 2013

Last Update Submit

September 16, 2013

Conditions

Keywords

TramadolChildrenHernioplastyWound infiltration

Outcome Measures

Primary Outcomes (1)

  • Pain intensity after wound infiltration with tramadol

    Faces scale

    1 month

Study Arms (2)

tramadol wound infiltration

ACTIVE COMPARATOR

2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously

Drug: tramadolDrug: 0.9% saline

tramadol intravenous administration

EXPERIMENTAL

2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration

Drug: tramadolDrug: 0.9% saline

Interventions

The volume of the solution was adequate to maintain the concentration of 2% tramadol

Also known as: tramal
tramadol intravenous administrationtramadol wound infiltration
tramadol intravenous administrationtramadol wound infiltration

Eligibility Criteria

Age3 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • children of both sexes
  • aged between 3 and 12 years
  • underwent hernioplasty

You may not qualify if:

  • children with bleeding disorders
  • using analgesic
  • sensitivity to any drug.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

São Paulo Hospital

São Paulo, São Paulo, 04023062, Brazil

Location

Related Publications (1)

  • Demiraran Y, Ilce Z, Kocaman B, Bozkurt P. Does tramadol wound infiltration offer an advantage over bupivacaine for postoperative analgesia in children following herniotomy? Paediatr Anaesth. 2006 Oct;16(10):1047-50. doi: 10.1111/j.1460-9592.2006.01910.x.

    PMID: 16972834BACKGROUND

MeSH Terms

Conditions

Hernia, Inguinal

Interventions

TramadolSaline Solution

Condition Hierarchy (Ancestors)

Hernia, AbdominalHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CyclohexanolsHexanolsFatty AlcoholsAlcoholsOrganic ChemicalsDimethylaminesMethylaminesAminesLipidsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Ana LA Giraldes, MD

    Federal University of São Paulo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

September 9, 2013

First Posted

September 17, 2013

Study Start

September 1, 2012

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

September 17, 2013

Record last verified: 2013-09

Locations